Evidence map›Paper›PMID 31304003›Full record

ArticleClinical sarcoma research2019

A rare presentation of carcinosarcoma of the bone in a young female; response with gemcitabine and docetaxel.

Nicholas King, Keshav Kukreja, Albina Murzabdillaeva, Yasir Ali, Jason Willis, Abhishek Maiti, Hilary Ma, Joan Bull

Abstract readCase Reports
In one paragraph

Article in Clinical sarcoma research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nicholas King1University of Texas Health Sciences Center at Houston, McGovern Medical School, Houston, TX USA.ORCID 0000-0002-5322-1953
Keshav Kukreja1University of Texas Health Sciences Center at Houston, McGovern Medical School, Houston, TX USA.
Albina Murzabdillaeva1University of Texas Health Sciences Center at Houston, McGovern Medical School, Houston, TX USA.
Yasir Ali1University of Texas Health Sciences Center at Houston, McGovern Medical School, Houston, TX USA.
Jason Willis2University of Texas Health Sciences Center MD Anderson Cancer Center, Houston, TX USA.
Abhishek Maiti2University of Texas Health Sciences Center MD Anderson Cancer Center, Houston, TX USA.
Hilary Ma2University of Texas Health Sciences Center MD Anderson Cancer Center, Houston, TX USA.
Joan Bull1University of Texas Health Sciences Center at Houston, McGovern Medical School, Houston, TX USA.

Funding

TRAINING FOR ACADEMIC ONCOLOGY/HEMATOLOGYT32CA009666 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Michael Davies, Courtney DiNardo · 1994 to 2026
$9.8M
NCI NIH HHS T32 CA009666
6 · The paper itself

Abstract

backgroundSarcomatoid carcinoma, or carcinosarcoma, is a neoplasm that contains both sarcomatous and carcinomatous elements. It is an extremely rare cancer most often arising from visceral organs. Here we report the seventh documented de novo case of carcinosarcoma of the bone, in a young female who showed initial clinical improvement with gemcitabine and docetaxel. CASE PRESENTATION: A 36-year-old Caucasian female presented with diffuse musculoskeletal pain that had progressed from her shoulder to her back, arm, and knee over 6 months. Imaging revealed diffuse sclerotic lesions of bilateral humeral heads, iliac and ischial bones, and thoracic and lumbar spine. Histopathologic examination of biopsies from the T9 vertebra and left femur showed mainly sarcomatous spindle cells with focal osteoid production. Immunostaining showed the cells to be OSCAR cytokeratin, patchy positive for pankeratin, and negative for CK7, GATA3, S100, SOX10, CD99, EMA, AE1/AE3, and HMW keratin indicative of an epithelial origin. After thorough clinical correlation, sarcomatoid carcinoma of a visceral organ was excluded and the diagnosis of primary sarcomatoid carcinoma of the bone was ultimately favored. She received chemotherapy with gemcitabine and docetaxel, and showed improvement at 6 months but ultimately passed 1 year post diagnosis.

conclusionsPrimary carcinosarcoma of the bone is an extremely rare malignancy. Early diagnosis is crucial as localized disease may be curable with resection. As shown in this case, combination chemotherapy with gemcitabine and docetaxel is a potential option in patients with unresectable or metastatic disease.

Indexed as

BoneCarcinosarcomaDocetaxelGemcitabineSarcomatoid carcinoma

Identifiers

PMID31304003
PMCPMC6604449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.